Buscar Company Acquires 70% Stake in Armorgenix

Aceragen Acquires Arrevus to Expand Late-Stage Rare Disease Pipeline

October 28, 2021

Biotechnology

Aceragen, Inc. acquired clinical-stage biopharmaceutical company Arrevus, Inc., adding Arrevus' lead oral anti-infective candidate ARV-1801 (renamed ACG-721) and several preclinical programs to Aceragen's rare-disease pipeline. The deal brings additional clinical and regulatory capabilities to Aceragen and is expected to be accretive as the company advances registrational and Phase 2/3 studies in cystic fibrosis and other orphan indications.

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

Astorg Mid‑Cap Acquires Majority Stake in hg medical

May 5, 2023

Medical Devices

Astorg Mid‑Cap, the German arm of pan‑European private equity firm Astorg, has signed an agreement to acquire a majority stake in hg medical from NORD Holding. The transaction — terms undisclosed — will support management succession (COO Craig Bluett to become CEO, founder Johannes Hagenmeyer to move to an advisory role) and fund organic growth, capacity expansion and external M&A to scale hg medical's orthopaedic implant contract‑manufacturing platform across extremities and spine.

Idera Pharmaceuticals Acquires Aceragen

September 28, 2022

Biotechnology

Idera Pharmaceuticals completed an all-stock acquisition of Aceragen, a privately held biotech focused on rare pulmonary and rheumatic diseases, adding Aceragen's lead programs ACG-701 and ACG-801 to Idera's pipeline. The transaction was structured as a stock-for-stock exchange, includes management appointments from Aceragen, and is expected to provide pro forma cash runway into Q3 2023 while advancing Aceragen's clinical milestones.

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.

Cuadrilla Capital Acquires Gluware

January 8, 2025

Cloud & SaaS

Cuadrilla Capital, a Santa Barbara-based enterprise software private equity firm, has acquired Gluware, an intelligent network automation company headquartered in Sacramento, California. The growth investment will accelerate Gluware’s product roadmap, support global expansion into the Global 2000 market, and enable acquisition-led growth and customer success investments; terms were not disclosed.